Qualigen Therapeutics(QLGN) - 2018 Q4 - Annual Report

For the fiscal year ended December 31, 2018 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 Commission File Number 001-37428 RITTER PHARMACEUTICALS, INC. FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share NASDAQ Capital Market Sec ...